Daily non-political popular news in brief.

Cancer Drug May Be Remedy For Rheumatoid Arthritis, Study Finds

09-30-2006 · ScienceDaily

The potent cancer drug Gleevec, used to combat leukemia and some gastrointestinal cancers, may be useful in treating rheumatoid arthritis, according to a team of researchers at the Stanford University School of Medicine.

Keywords: cancer, drug, remedy, rheumatoid, arthritis, study, arthriti

« Previous | Next »

Similar news on "Cancer Drug May Be Remedy For Rheumatoid Arthritis, Study Finds":

Annals of Internal Medicine tip sheet for March 20, 2007
03-19-2007 · EurekAlert!
The following articles are featured in the upcoming Annals of Internal Medicine: "Flexible Use of Drugs with Close Patient Follow-up Can Successfully Control Rheumatoid Arthritis;" "Osteoporosis Drug Strengthens Bones in Men with Prostate Cancer," and "Experts Show Physicians How to Initiate and Carry Through Timely and Effective Discussions about Hospice with Dying Patients."
Similar news · Read more »
Anti-malarial drug may reduce risk of diabetes for patients with rheumatoid arthritis
07-10-2007 · EurekAlert!
Preliminary research suggests that use of the anti-malarial drug hydroxychloroquine may help reduce the risk of the development of diabetes in patients with rheumatoid arthritis, according to a study in the July 11 issue of JAMA.
Similar news · Read more »
Common rheumatoid arthritis treatment shows potential for diabetes prevention
07-10-2007 · EurekAlert!
Fewer rheumatoid arthritis patients treated with the drug hydroxychloroquine went on to develop diabetes compared to those who never took the drug, according to a 20-plus-year University of Pittsburgh School of Medicine-led study reported today in the Journal of the American Medical Association. In addition, those using HCQ were less likely to take medications to manage diabetes after diagnosis. The study found risk declined a dramatic 77 percent after four years of HCQ treatment.
Similar news · Read more »
A new target for the treatment of breast cancer
01-11-2007 · EurekAlert!
The active ingredient in a drug currently being tested to treat rheumatoid arthritis might also one day serve as an effective means of treating one of the deadliest forms of breast cancer. Berkeley Lab researchers have demonstrated that inhibiting the activity of the protease enzyme known as TACE can deprive tumor cells of a key factor needed for their proliferation. TACE is strongly present in a form of breast cancer which responds poorly to current therapies.
Similar news · Read more »
New Actemra data shows significant benefit for patients suffering from rheumatoid arthritis
11-08-2007 · EurekAlert!
The innovative new rheumatoid arthritis drug Actemra has been shown to significantly improve the signs and symptoms of rheumatoid arthritis in patients who failed to achieve an adequate response to traditional disease modifying agents. Exciting new data from the TOWARD1 study, being presented as a late breaker, at the American College of Rheumatology Annual Scientific Meeting in Boston, Nov. 6-11, reinforce the benefit of tackling RA through the inhibition of the IL-6 pathway.
Similar news · Read more »
The link between rheumatoid arthritis and cancer
02-27-2007 · EurekAlert!
The first study to investigate whether patients with RA who develop cancer have a decreased rate of survival, featured in the March 2007 issue of Arthritis & Rheumatism, also examined the impact of rheumatic disease on overall cancer incidence.
Similar news · Read more »
Enbrel safety data for up to 8 years in patients with juvenile rheumatoid arthritis
06-13-2007 · EurekAlert!
Amgen and Wyeth Pharmaceuticals, a division of Wyeth, today announced the presentation of additional data that showed that the safety profile of Enbrel was maintained with long-term use in patients with moderate-to-severe juvenile rheumatoid arthritis who completed up to eight years of therapy. The study results will be presented at the European League Against Rheumatism Annual Congress, an international rheumatology meeting, in Barcelona, Spain.
Similar news · Read more »
Mayo Clinic Cancer Center -- Working on the tough cases
12-11-2006 · EurekAlert!
Mayo Clinic Cancer Center, in collaboration with researchers from the University of Iowa, today presented results of a Phase II clinical study indicating that an oral drug, tipifarnib, can stall or reverse disease progression for patients with relapsed aggressive non-Hodgkin lymphoma.
Similar news · Read more »
Penn's Abramson Cancer Center part of major phase III study for myeloma
11-21-2007 · EurekAlert!
Researchers from the UPenn's Abramson Cancer Center announced today that findings from two international clinical trials show unprecedented survival for patients with myeloma, a cancer the blood-making cells of bone marrow. Findings show that with the oral drug lenalidomide, in combination with dexamethasone, patients significantly improved by all measures where previous treatments had failed -- including a median survival of nearly three years -- the longest median survival known for this difficult to treat patient group.
Similar news · Read more »
Drug study for brain cancer shows promising results
12-13-2007 · EurekAlert!
A clinical study conducted at Henry Ford Hospital on the use of a drug to extend the survival of patients with the most common and aggressive type of brain cancer, has yielded results that were significantly better than expected.
Similar news · Read more »